TZDs are PPAR-γ agonists, introduced initially to treat type II diabetes mellitus; they have been demonstrated to reduce albuminuria in type 2 diabetes [15], as well as to decrease proteinuria in non-diabetic kidney diseases [16]. Here, PPARG is linked to type 2 diabetes mellitus.